북미와 유럽의 전임상 의료기기 시험 서비스 시장 : 시장 규모, 점유율, 동향 분석 보고서-서비스별, 지역별, 부문별 예측(2025-2030년)
North America And Europe Preclinical Medical Device Testing Services Market Size, Share & Trends Analysis Report By Service, By Region, And Segment Forecasts, 2025 - 2030
상품코드:1609940
리서치사:Grand View Research
발행일:2024년 11월
페이지 정보:영문 120 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
북미와 유럽의 전임상 의료기기 시험 서비스 시장의 성장 및 동향 :
Grand View Research, Inc.의 최신 보고서에 따르면, 북미와 유럽의 전임상 의료기기 시험 서비스 시장 규모는 2025년부터 2030년까지 연평균 복합 성장률(CAGR) 9.3%로 확대될 전망이며, 2030년에는 31억 4,000만 달러에 달할 전망입니다.
자사의 시험 능력이 부족한 소형 의료기기 증가와 제품 설계의 복잡성이 시장의 성장을 가속하는 주요 요인이 되고 있습니다.
지난 10년간 시장에서 사업을 전개하는 기업의 수가 증가하고 있습니다. 이 숫자의 많고 적음이 치열한 경합을 낳고 있습니다. 시장을 유지하기 위해 수비와 공격의 마케팅 전략이 혼재되어 있습니다. 예를 들어 광범위한 연구 개발, 경쟁 가격 설정, 신제품 출시, 공동 개발, 지역 확대, M&A 등입니다.
COVID-19의 대유행은 이러한 서비스에 대한 큰 수요를 낳았습니다. 이 증가는 전반에는 그리 크지 않았지만 업계가 팬데믹 시 운영에 적응하면서 후반에는 더욱 두드러졌다. 개인 보호구의 생산과 테스트가 증가하면서 코로나 때문에 중단되었던 몇몇 프로젝트가 개인 보호구를 재개했습니다. 팬데믹으로 인해 다양한 의료기기의 수요가 높아져 수술에 필요한 것부터 주의가 어긋나고 있습니다. 코로나19 예방접종, 인공호흡기, 펄스옥시미터는 수요가 증가하고 있는 주요 상품입니다.
북미와 유럽 전임상 의료기기 시험 서비스 시장 하이라이트
2024년에는 생체적합성 시험 분야가 44.7%의 매출 점유율을 차지하고 시장을 독점했습니다. 의료기기 제조업체에게 안전하고 효과적인 제품을 제조하는 것은 최우선 사항이며 품질보증은 이 목적을 달성하는 데 매우 중요합니다.
화학검사 분야는 예측기간 중 가장 빠른 CAGR 9.6%로 상승할 것으로 예상되고 있습니다. 화학 검사는 가치 사슬 전체에서 의료 기기 산업을 지원합니다.
북미의 전임상 의료기기 시험 서비스 시장은 2024년에 55.0%의 큰 점유율로 우위를 차지하고 있습니다.
목차
제1장 조사 방법 및 범위
제2장 주요 요약
제3장 북미와 유럽의 전임상 의료기기 시험 서비스 시장의 변수, 동향 및 범위
시장 계통 전망
상위 시장 전망
관련 및 부수 시장 전망
시장 역학
시장 견인 요인 분석
시장 성장 억제요인 분석
시장 분석 도구
Porter's Five Forces 분석
PESTEL 분석
COVID-19의 영향 분석
제4장 북미와 유럽의 전임상 의료기기 시험 서비스 시장 : 서비스별 추정 및 동향 분석
부문 대시보드
북미 및 유럽 전임상 의료기기 시험 서비스 시장 : 변동 분석
북미 및 유럽의 전임상 의료기기 시험 서비스의 규모 및 동향 분석(2018-2030년)
생체 적합성 시험
화학적 검사
미생물학 및 무균 시험
바이오바덴 측정
발열물질 및 엔도톡신 검사
무균시험 및 검증
항균 활성 시험
기타
패키지 검증
제5장 북미와 유럽의 전임상 의료기기 시험 서비스 시장 : 지역별 추정 및 동향 분석
지역별 시장 점유율 분석(2024년, 2030년)
지역 시장 대시보드
북미
미국
캐나다
멕시코
유럽
영국
독일
프랑스
이탈리아
스페인
덴마크
스웨덴
노르웨이
제6장 경쟁 구도
기업 분류
기업시장 포지셔닝 분석(2023년)
기업 프로파일
SGS SA
Toxikon, Inc.
Eurofins Scientific
Pace Analytical Services LLC
Intertek Group Plc
WUXI APPTEC
TUV SUD AG
Sterigenics International LLC
Nelson Labs
North American Science Associates, Inc.
American Preclinical Services
Charles River Laboratories International, Inc.
AJY
영문 목차
영문목차
North America And Europe Preclinical Medical Device Testing Service Market Growth & Trends:
The North America and Europe preclinical medical device testing services market size is expected to reach USD 3.14 billion by 2030, expanding at a CAGR of 9.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increase in the number of small medical devices lacking in-house testing capabilities and complexity in product design are the major factors driving the growth of the market.
There has been an increase in the number of players operating in the market over the last decade. Due to this large number, it has witnessed fierce competition. To sustain the market, a mix of defensive and offensive marketing strategies is used. For instance, extensive R&D, competitive pricing, new product launches, collaborative development, regional expansion, and mergers and acquisitions.
The COVID-19 pandemic has created a huge demand for these services. The rise was not significant in the first half, but it became more significant in the second as the industry adapted to operating during the pandemic. There has been an increase in the production and testing of personal protective equipment, and several projects that were put on hold because of COVID have resumed personal protective equipment. The epidemic has increased demand for a wide range of medical gadgets, diverting attention from those needed for surgery. COVID-19 vaccinations, ventilators, and pulse oximeters are the main goods seeing an increase in demand.
North America And Europe Preclinical Medical Device Testing Services Market Highlights
In 2024, the biocompatibility tests segment dominated the market, accounting for a revenue share of 44.7%. Manufacturing safe and effective goods is a top priority for medical device manufacturers, and quality assurance is crucial in accomplishing this aim.
The chemistry test segment is expected to rise with the fastest CAGR of 9.6% in the forecast period. Chemistry tests support the medical device industry across the value chain.
North America preclinical medical device testing services market dominated in 2024 with a larger share of 55.0%.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR's Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity Flow Analysis
1.6.2. Bottom-up Approach
1.7. List of Secondary Sources
1.8. List of Abbreviations
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. North America and Europe Preclinical Medical Device Testing Services Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Complexity in product design
3.2.1.2. Strict approval norms
3.2.1.3. Increase in number of small medical device lacking in-house testing capabilities
3.2.1.4. Intense competition in medical device industry
3.2.2. Market restraint analysis
3.2.2.1. Legal and Regulatory Issues
3.3. Market Analysis Tools
3.3.1. Porter's Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. North America and Europe Preclinical Medical Device Testing Services Market: Service Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. North America and Europe Preclinical Medical Device Testing Services Market; Method Movement Analysis
4.3. North America and Europe Preclinical Medical Device Testing Services Size & Trend Analysis, by Method, 2018 to 2030 (USD Million)
4.4. Biocompatibility Tests
4.4.1. Biocompatibility tests market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Chemistry Test
4.5.1. Chemistry test market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Microbiology & Sterility Testing
4.6.1. Microbiology & sterility testing market estimates and forecasts 2018 to 2030 (USD Million)
4.6.2. Bioburden Determination
4.6.2.1. Bioburden determination market estimates and forecasts 2018 to 2030 (USD Million)
4.6.3. Pyrogen & Endotoxin Testing
4.6.3.1. Pyrogen & endotoxin testing market estimates and forecasts 2018 to 2030 (USD Million)
4.6.4. Sterility Test and Validation
4.6.4.1. Sterility test and validation market estimates and forecasts 2018 to 2030 (USD Million)
4.6.4.2. Ethylene Oxide (EO) gas sterilization
4.6.4.2.1. Ethylene oxide (EO) gas sterilization market estimates and forecasts 2018 to 2030 (USD Million)
4.6.4.3. Gamma-irradiation
4.6.4.3.1. Gamma-irradiation market estimates and forecasts 2018 to 2030 (USD Million)
4.6.4.4. E-beam sterilization
4.6.4.4.1. E-beam sterilization market estimates and forecasts 2018 to 2030 (USD Million)
4.6.4.5. X-ray sterilization
4.6.4.5.1. X-ray sterilization market estimates and forecasts 2018 to 2030 (USD Million)
4.6.5. Antimicrobial Activity Testing
4.6.5.1. Antimicrobial activity testing market estimates and forecasts 2018 to 2030 (USD Million)
4.6.6. Others
4.6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Package Validation
4.7.1. Package validation market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. North America and Europe Preclinical Medical Device Testing Services Market: Regional Estimates & Trend Analysis
5.1. Regional Market Share Analysis, 2024 & 2030
5.2. Regional Market Dashboard
5.3. North America
5.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.3.2. U.S.
5.3.2.1. Key country dynamics
5.3.2.2. Competitive scenario
5.3.2.3. Regulatory framework
5.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
5.3.3. Canada
5.3.3.1. Key country dynamics
5.3.3.2. Competitive scenario
5.3.3.3. Regulatory framework
5.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
5.3.4. Mexico
5.3.4.1. Key country dynamics
5.3.4.2. Competitive scenario
5.3.4.3. Regulatory framework
5.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
5.4. Europe
5.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.4.2. UK
5.4.2.1. Key country dynamics
5.4.2.2. Competitive scenario
5.4.2.3. Regulatory framework
5.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Germany
5.4.3.1. Key country dynamics
5.4.3.2. Competitive scenario
5.4.3.3. Regulatory framework
5.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. France
5.4.4.1. Key country dynamics
5.4.4.2. Competitive scenario
5.4.4.3. Regulatory framework
5.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
5.4.5. Italy
5.4.5.1. Key country dynamics
5.4.5.2. Competitive scenario
5.4.5.3. Regulatory framework
5.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
5.4.6. Spain
5.4.6.1. Key country dynamics
5.4.6.2. Competitive scenario
5.4.6.3. Regulatory framework
5.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
5.4.7. Denmark
5.4.7.1. Key country dynamics
5.4.7.2. Competitive scenario
5.4.7.3. Regulatory framework
5.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
5.4.8. Sweden
5.4.8.1. Key country dynamics
5.4.8.2. Competitive scenario
5.4.8.3. Regulatory framework
5.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
5.4.9. Norway
5.4.9.1. Key country dynamics
5.4.9.2. Competitive scenario
5.4.9.3. Regulatory framework
5.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Company Categorization
6.2. Company Market Position Analysis, 2023
6.3. Company Profiles
6.3.1. SGS SA
6.3.1.1. Company overview
6.3.1.2. Financial performance
6.3.1.3. Service benchmarking
6.3.1.4. Strategic initiatives
6.3.2. Toxikon, Inc.
6.3.2.1. Company overview
6.3.2.2. Financial performance
6.3.2.3. Service benchmarking
6.3.2.4. Strategic initiatives
6.3.3. Eurofins Scientific
6.3.3.1. Company overview
6.3.3.2. Financial performance
6.3.3.3. Service benchmarking
6.3.3.4. Strategic initiatives
6.3.4. Pace Analytical Services LLC
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Service benchmarking
6.3.4.4. Strategic initiatives
6.3.5. Intertek Group Plc
6.3.5.1. Company overview
6.3.5.2. Financial performance
6.3.5.3. Service benchmarking
6.3.5.4. Strategic initiatives
6.3.6. WUXI APPTEC
6.3.6.1. Company overview
6.3.6.2. Financial performance
6.3.6.3. Service benchmarking
6.3.6.4. Strategic initiatives
6.3.7. TUV SUD AG
6.3.7.1. Company overview
6.3.7.2. Financial performance
6.3.7.3. Service benchmarking
6.3.7.4. Strategic initiatives
6.3.8. Sterigenics International LLC
6.3.8.1. Company overview
6.3.8.2. Financial performance
6.3.8.3. Service benchmarking
6.3.8.4. Strategic initiatives
6.3.9. Nelson Labs
6.3.9.1. Company overview
6.3.9.2. Financial performance
6.3.9.3. Service benchmarking
6.3.9.4. Strategic initiatives
6.3.10. North American Science Associates, Inc.
6.3.10.1. Company overview
6.3.10.2. Financial performance
6.3.10.3. Service benchmarking
6.3.10.4. Strategic initiatives
6.3.11. American Preclinical Services
6.3.11.1. Company overview
6.3.11.2. Financial performance
6.3.11.3. Service benchmarking
6.3.11.4. Strategic initiatives
6.3.12. Charles River Laboratories International, Inc.
